Αρχική World News Teclistamab Significantly Improves Survival Among Patients with Multiple Myeloma Who Previously Received... World News Teclistamab Significantly Improves Survival Among Patients with Multiple Myeloma Who Previously Received One To Three Lines of Treatment Από Ogkologos - 16 Ιουνίου, 2026 275 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-9 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Heartburn Medications Pulled From Shelves Because They May Cause Cancer 13 Ιανουαρίου, 2020 Pelabresib Plus Ruxolitinib Improves Signs of Underlying Myelofibrosis Pathobiology and Provides... 25 Μαρτίου, 2025 FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive,... 9 Σεπτεμβρίου, 2026 KRASG12 Mutations Are Biomarkers for Reduced Overall Survival Benefit of Treatment... 14 Μαρτίου, 2023 Φόρτωση περισσοτέρων HOT NEWS ESMO Gynaecological Cancers Congress 2023 One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides... FDA Approves Brentuximab Vedotin in Combination with Chemotherapy for Paediatric Patients... The path to least resistance: How our researchers are outsmarting cancer’s...